Is there an optimal adjunct therapy to traditional cytotoxic induction?

Michaelis, Laura C.

doi:10.1016/j.beha.2021.101326

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, In preclinical studies, cladribine, a purine analogue, has demonstrated the ability to enhance the intracellular uptake of cytarabine in leukemic blasts, suggesting a potential synergistic effect between cladribine and cytarabine [ 13 ]. The utilization of cladribine as adjuvant therapy has been a focus of extensive research by the Polish Adult Leukemia Group, conducting several of the most significant studies on the subject [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Exploration of novel 6,8,9-trisubstituted purine analogues: synthesis, in vitro biological evaluation, and their effect on human cancer cells

POLAT,

ŞAHİN,

ATALAY

et al. 2024

Turkish Journal of Chemistry

View full text Add to dashboard Cite

Cancer, a leading global cause of mortality, demands continuous advancements in therapeutic strategies. This study focuses on the design and synthesis of a novel series of purine derivatives, specifically 6-(substituted phenyl piperazine)-8-(4-phenoxyphenyl)-9-cyclopentyl purine derivatives (5–11). The motivation behind this endeavor lies in addressing acquired resistance mechanisms in cancer cells, a significant hurdle in current treatment modalities. The synthesis, starting from 4,6-dichloro-5-nitropyrimidine, involves a multi-step process, resulting in seven new purine derivatives. Biological evaluation against human liver, colon, and breast cancer cells (Huh7, HCT116, and MCF7, respectively) was performed using the SRB assay. Among the synthesized analogs, compounds 5 and 6, exhibited notable cytotoxic activity, surpassing clinically used positive controls 5-Fluorouracil and Fludarabine in terms of efficacy. This research underscores the potential of purine derivatives with a phenyl group at the C-8 position as a scaffold for developing compounds with improved anticancer properties. The findings offer insights for future exploration and development of novel agents in cancer pharmaceutical research.

show abstract

Section: Introductionmentioning

confidence: 99%

Exploration of novel 6,8,9-trisubstituted purine analogues: synthesis, in vitro biological evaluation, and their effect on human cancer cells

POLAT,

ŞAHİN,

ATALAY

et al. 2024

Turkish Journal of Chemistry

View full text Add to dashboard Cite

show abstract

Microcosting Analysis of Hematopoietic Stem Cell Transplantation and Chemotherapy with Intermediate Doses of Cytarabine in the Treatment of Acute Myeloid Leukemia

Chiesa

Madeira

Pontes

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Acute myeloid leukemia (AML) is considered a costly disease. Although induction of remission is a critical factor for overall survival (OS) in patients with AML, the fundamental decision after induction is the best post-remission treatment strategy. Depending on risk stratification, the patient may receive consolidation with cycles of intermediate doses of cytarabine, auto-HSCT or allo-HSCT, according to the availability of each service and the availability of a compatible donor. Both strategies are valid for low-risk AML and in the impossibility of an allogeneic or haploidentical transplant also for intermediate risk. Literature data indicate that the safety and effectiveness of consolidation therapy with intermediate dose cytarabine or auto-HSCT do not differ from each other, and the cost can help physicians and health managers in their choice. Methods: We aimed to compare the cost of both treatments of second consolidation in adult patients with de novo AML, 18 - 60 years old, included in the ICAML (International Consortium of Acute Myeloid Leukemia) protocol and analyzed through the microcosting methodology, estimating the direct medical costs of the alternative consolidation therapies under analysis. Results: Retrospectively, from 09/01/15 to 09/01/19, we analyzed 9 patients from the Hospital das Clínicas de Ribeirão Preto, 5 patients treated with auto-HSCT, and 4 patients treated with intermediate doses of cytarabine. The average cost of auto-HSCT was BRL 114.212,78, and that of cytarabine was BRL 121.980,93. Conclusion: In both groups and regardless of the treatment cycle, we observed that the inputs with the greatest economic impact were hospital admissions, mainly due to infections

show abstract

Is there an optimal adjunct therapy to traditional cytotoxic induction?

Cited by 2 publications

References 22 publications

Exploration of novel 6,8,9-trisubstituted purine analogues: synthesis, in vitro biological evaluation, and their effect on human cancer cells

Exploration of novel 6,8,9-trisubstituted purine analogues: synthesis, in vitro biological evaluation, and their effect on human cancer cells

Microcosting Analysis of Hematopoietic Stem Cell Transplantation and Chemotherapy with Intermediate Doses of Cytarabine in the Treatment of Acute Myeloid Leukemia

Contact Info

Product

Resources

About